Michigan Proposes 57% Vape Tax in $800M Revenue Plan

Regulations
Feb.23
Michigan Proposes 57% Vape Tax in $800M Revenue Plan
Michigan Governor Gretchen Whitmer’s FY2027 executive budget proposes a new 57% wholesale tax on vaping products and oral nicotine items as part of a broader $800 million revenue package aimed at stabilizing Medicaid funding.

Key Points

 

  • Michigan proposes a 57% wholesale tax on vape and oral nicotine products.

 

  • The nicotine tax is expected to raise about $95 million annually.

 

  • Cigarette taxes would increase from $2 to $3 per pack.

 

  • The broader revenue package aims to generate nearly $800 million.

 

  • Funds are primarily intended to stabilize Medicaid coverage.

 


 

2Firsts, February 23, 2026

 

The following is compiled from budget documents released by the Office of Governor Gretchen Whitmer and coverage by Michigan Advance and Bridge Michigan. Michigan Governor Gretchen Whitmer has proposed significant tax increases on vaping and nicotine products as part of her FY2027 executive budget plan.

 

The $88.1 billion budget includes a revenue package projected to raise nearly $800 million annually. A central element is a proposed 57% wholesale tax on vaping products and oral nicotine items, including products such as Zyn. The administration estimates the measure would generate approximately $95 million per year.

 

In addition, the proposal would raise the cigarette wholesale tax from $2 to $3 per pack, generating an estimated $232 million annually. Together, tobacco-related measures would contribute more than $300 million toward the broader revenue target.

 

The nicotine tax changes are designed to help stabilize Michigan’s Medicaid program, which insures more than 2.6 million residents — roughly one-quarter of the state’s population. State officials warn that federal funding changes have created financial pressure on the program.

 

Other revenue measures in the proposal include a new 4.7% tax on digital advertisements served in Michigan, higher tax rates on large online casino operators, a per-wager sports betting tax, and the elimination of deductions for promotional sports bets.

 

Governor Whitmer’s administration has framed the targeted tax approach as a way to fund education and healthcare priorities without increasing broad-based income or sales taxes.

 

However, the proposal faces political hurdles. Michigan’s Republican-controlled House has already indicated opposition to tax increases, setting up negotiations that will determine whether the nicotine tax proposal advances.

 

(Cover Image Governor Gretchen Whitmer | Image Sources: Office of Governor Gretchen Whitmer)

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan Senate Bill 786 Seeks to Ban Sale of Vapes With Metal Heating Elements
Michigan lawmakers introduced Senate Bill 786 on February 18, 2026, proposing to prohibit the sale or transfer of vapor products that contain heating elements unless those elements are made of or encased in glass or ceramic materials
Regulations
Feb.21
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
The Oregon Senate voted 26–1 to pass Senate Bill 1571, a measure redefining tobacco products to include nicotine pouches and restricting their sale to individuals under 21.
Regulations
Feb.23
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11